All News

A nagging political question still hovers over the EU funding debate: should the roughly €54 billion be spent exclusively on Europe's established crème de la scientific crème?

Every little bit helps if you are a start up looking for market opportunities. Launchpad Europe has a methodology and a proposition.

Cancer Research UK plans to rescue viable compounds stuck on the shelves of pharma and biotech companies.

The European Commission told universities to modernise and pull their weight in the EU’s plans to become the leading knowledge-based economy, as it released an action plan for change.

Having our cake and eating it – Europe's food research strategy wants the most appetising food to be the healthy option, too.

The European Union has declared its pilot programme to promote the use of hydrogen-powered vehicles a success – and announced a further €105 million scheme.

After raising £910,000 from a Phase Ib/IIa study of its lead product, a treatment for multiple sclerosis, Apitope Technology Ltd is looking for first round funding of up to £7 million.

Tracking goods by Radio Frequency Identification is said to be the next big market for wireless communication. But some in the field doubt the technology is mature enough.

Greek scientists have developed a way of coating the films used to package foods and drugs, and are now looking for partnerships with companies.

AstraZeneca’s outrageously high bid for Cambridge Antibody Technology underscores the heat rising in the biotech market.

The British National Space Centre recently launched its annual survey of the UK's space industry. There are few superstars out there. But there are opportunities on the launchpad.

Could this be the only time you read about the World Cup at Science|Business?

Cambridge Enterprise has more experience than most at turning scientific into successful businesses. A new book passes on some of their wisdom.

The Information Society Technology programme of the EU's Framework 6 has a new web site aimed at the New Member States and Associate Candidate Countries.

Nanotechnology is beginning to leave the laboratory and hit the high street – but health scares could stop this commercialisation process in its tracks.